Skip to main content

ADVERTISEMENT

Diffuse Large B-Cell Lymphoma

Conference Insider
12/15/2020
Patients with relapsed/refractory DLBCL given AUTO3 (a CD19/22 dual targeting CAR-T therapy) plus pembrolizumab had durable responses.
Patients with relapsed/refractory DLBCL given AUTO3 (a CD19/22 dual targeting CAR-T therapy) plus pembrolizumab had durable responses.
Patients with...
12/15/2020
Oncology
Conference Insider
12/10/2020
Avelumab plus R-CHOP yielded high rates of complete response with manageable toxicity in a cohort of patients with newly diagnosed DLBCL.
Avelumab plus R-CHOP yielded high rates of complete response with manageable toxicity in a cohort of patients with newly diagnosed DLBCL.
Avelumab plus R-CHOP yielded...
12/10/2020
Oncology
Conference Insider
12/07/2020
Single-agent mosunetuzumab shows efficacy, remarkable safety, as a chemo-free option for previously untreated elderly/unfit patients with DLBCL.
Single-agent mosunetuzumab shows efficacy, remarkable safety, as a chemo-free option for previously untreated elderly/unfit patients with DLBCL.
Single-agent mosunetuzumab shows...
12/07/2020
Oncology
medical
Conference Insider
12/03/2020
Polatuzumab vedotin plus venetoclax with rituximab shows promise in the treatment of patients with R/R DLBCL, according to phase 1b/2 study findings.
Polatuzumab vedotin plus venetoclax with rituximab shows promise in the treatment of patients with R/R DLBCL, according to phase 1b/2 study findings.
Polatuzumab vedotin plus...
12/03/2020
Oncology
sh
Conference Insider
12/02/2020
According to data being presented at the virtual ASH Annual Meeting and Exposition, fragility in patients with DLBCL is significantly associated with 1-year mortality.
According to data being presented at the virtual ASH Annual Meeting and Exposition, fragility in patients with DLBCL is significantly associated with 1-year mortality.
According to data being...
12/02/2020
Oncology